NEW YORK CITY, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intellia Therapeutics, Inc. ("Intellia" or "the Company") (NASDAQ:NTLA). Investors who purchased Intellia securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/NTLA. […]

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson ("J&J" or "the Company") (NYSE:JNJ). Investors who purchased J&J securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/JNJ. Investigation

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Liberty TripAdvisor Holdings, Inc. ("Liberty TripAdvisor") (OTCMKTS:LTRPA) and TripAdvisor. Investors who purchased Liberty TripAdvisor and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the

NEW YORK CITY, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dick’s Sporting Goods, Inc. ("Dick’s" or "the Company") (NYSE:DKS). Investors who purchased Dick’s securities prior to May 25, 2022, and continue to hold to the present, are encouraged to

NEW YORK CITY, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI). Investors who purchased Inari securities prior to March 10, 2021, and continue to hold to the present, are encouraged to obtain

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Five Below, Inc. ("Five Below" or "the Company") (NASDAQ:FIVE). Investors who purchased Five Below securities prior to December 1, 2022, and continue to hold to the present, are encouraged to

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against BioAge Labs, Inc. ("BioAge" or the "Company") (NASDAQ:BIOA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged

NEW YORK CITY, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Transocean Ltd.("Transocean" or the "Company") (NYSE:RIG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Transocean and certain of its officers and/or directors have

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ:AZN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether AstraZeneca and certain of its officers and/or directors have

NEW YORK, NY / ACCESSWIRE / January 22, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Applied Therapeutics, Inc. ("Applied Therapeutics" or the "Company") (NASDAQ:APLT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged